Cargando…

Orthogonal cytokine engineering enables novel synthetic effector states escaping canonical exhaustion in tumor-rejecting CD8(+) T cells

To date, no immunotherapy approaches have managed to fully overcome T-cell exhaustion, which remains a mandatory fate for chronically activated effector cells and a major therapeutic challenge. Understanding how to reprogram CD8(+) tumor-infiltrating lymphocytes away from exhausted effector states r...

Descripción completa

Detalles Bibliográficos
Autores principales: Corria-Osorio, Jesus, Carmona, Santiago J., Stefanidis, Evangelos, Andreatta, Massimo, Ortiz-Miranda, Yaquelin, Muller, Tania, Rota, Ioanna A., Crespo, Isaac, Seijo, Bili, Castro, Wilson, Jimenez-Luna, Cristina, Scarpellino, Leonardo, Ronet, Catherine, Spill, Aodrenn, Lanitis, Evripidis, Romero, Pedro, Luther, Sanjiv A., Irving, Melita, Coukos, George
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10154250/
https://www.ncbi.nlm.nih.gov/pubmed/37081150
http://dx.doi.org/10.1038/s41590-023-01477-2
_version_ 1785036087671914496
author Corria-Osorio, Jesus
Carmona, Santiago J.
Stefanidis, Evangelos
Andreatta, Massimo
Ortiz-Miranda, Yaquelin
Muller, Tania
Rota, Ioanna A.
Crespo, Isaac
Seijo, Bili
Castro, Wilson
Jimenez-Luna, Cristina
Scarpellino, Leonardo
Ronet, Catherine
Spill, Aodrenn
Lanitis, Evripidis
Romero, Pedro
Luther, Sanjiv A.
Irving, Melita
Coukos, George
author_facet Corria-Osorio, Jesus
Carmona, Santiago J.
Stefanidis, Evangelos
Andreatta, Massimo
Ortiz-Miranda, Yaquelin
Muller, Tania
Rota, Ioanna A.
Crespo, Isaac
Seijo, Bili
Castro, Wilson
Jimenez-Luna, Cristina
Scarpellino, Leonardo
Ronet, Catherine
Spill, Aodrenn
Lanitis, Evripidis
Romero, Pedro
Luther, Sanjiv A.
Irving, Melita
Coukos, George
author_sort Corria-Osorio, Jesus
collection PubMed
description To date, no immunotherapy approaches have managed to fully overcome T-cell exhaustion, which remains a mandatory fate for chronically activated effector cells and a major therapeutic challenge. Understanding how to reprogram CD8(+) tumor-infiltrating lymphocytes away from exhausted effector states remains an elusive goal. Our work provides evidence that orthogonal gene engineering of T cells to secrete an interleukin (IL)-2 variant binding the IL-2Rβγ receptor and the alarmin IL-33 reprogrammed adoptively transferred T cells to acquire a novel, synthetic effector state, which deviated from canonical exhaustion and displayed superior effector functions. These cells successfully overcame homeostatic barriers in the host and led—in the absence of lymphodepletion or exogenous cytokine support—to high levels of engraftment and tumor regression. Our work unlocks a new opportunity of rationally engineering synthetic CD8(+) T-cell states endowed with the ability to avoid exhaustion and control advanced solid tumors.
format Online
Article
Text
id pubmed-10154250
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group US
record_format MEDLINE/PubMed
spelling pubmed-101542502023-05-04 Orthogonal cytokine engineering enables novel synthetic effector states escaping canonical exhaustion in tumor-rejecting CD8(+) T cells Corria-Osorio, Jesus Carmona, Santiago J. Stefanidis, Evangelos Andreatta, Massimo Ortiz-Miranda, Yaquelin Muller, Tania Rota, Ioanna A. Crespo, Isaac Seijo, Bili Castro, Wilson Jimenez-Luna, Cristina Scarpellino, Leonardo Ronet, Catherine Spill, Aodrenn Lanitis, Evripidis Romero, Pedro Luther, Sanjiv A. Irving, Melita Coukos, George Nat Immunol Technical Report To date, no immunotherapy approaches have managed to fully overcome T-cell exhaustion, which remains a mandatory fate for chronically activated effector cells and a major therapeutic challenge. Understanding how to reprogram CD8(+) tumor-infiltrating lymphocytes away from exhausted effector states remains an elusive goal. Our work provides evidence that orthogonal gene engineering of T cells to secrete an interleukin (IL)-2 variant binding the IL-2Rβγ receptor and the alarmin IL-33 reprogrammed adoptively transferred T cells to acquire a novel, synthetic effector state, which deviated from canonical exhaustion and displayed superior effector functions. These cells successfully overcame homeostatic barriers in the host and led—in the absence of lymphodepletion or exogenous cytokine support—to high levels of engraftment and tumor regression. Our work unlocks a new opportunity of rationally engineering synthetic CD8(+) T-cell states endowed with the ability to avoid exhaustion and control advanced solid tumors. Nature Publishing Group US 2023-04-20 2023 /pmc/articles/PMC10154250/ /pubmed/37081150 http://dx.doi.org/10.1038/s41590-023-01477-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Technical Report
Corria-Osorio, Jesus
Carmona, Santiago J.
Stefanidis, Evangelos
Andreatta, Massimo
Ortiz-Miranda, Yaquelin
Muller, Tania
Rota, Ioanna A.
Crespo, Isaac
Seijo, Bili
Castro, Wilson
Jimenez-Luna, Cristina
Scarpellino, Leonardo
Ronet, Catherine
Spill, Aodrenn
Lanitis, Evripidis
Romero, Pedro
Luther, Sanjiv A.
Irving, Melita
Coukos, George
Orthogonal cytokine engineering enables novel synthetic effector states escaping canonical exhaustion in tumor-rejecting CD8(+) T cells
title Orthogonal cytokine engineering enables novel synthetic effector states escaping canonical exhaustion in tumor-rejecting CD8(+) T cells
title_full Orthogonal cytokine engineering enables novel synthetic effector states escaping canonical exhaustion in tumor-rejecting CD8(+) T cells
title_fullStr Orthogonal cytokine engineering enables novel synthetic effector states escaping canonical exhaustion in tumor-rejecting CD8(+) T cells
title_full_unstemmed Orthogonal cytokine engineering enables novel synthetic effector states escaping canonical exhaustion in tumor-rejecting CD8(+) T cells
title_short Orthogonal cytokine engineering enables novel synthetic effector states escaping canonical exhaustion in tumor-rejecting CD8(+) T cells
title_sort orthogonal cytokine engineering enables novel synthetic effector states escaping canonical exhaustion in tumor-rejecting cd8(+) t cells
topic Technical Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10154250/
https://www.ncbi.nlm.nih.gov/pubmed/37081150
http://dx.doi.org/10.1038/s41590-023-01477-2
work_keys_str_mv AT corriaosoriojesus orthogonalcytokineengineeringenablesnovelsyntheticeffectorstatesescapingcanonicalexhaustionintumorrejectingcd8tcells
AT carmonasantiagoj orthogonalcytokineengineeringenablesnovelsyntheticeffectorstatesescapingcanonicalexhaustionintumorrejectingcd8tcells
AT stefanidisevangelos orthogonalcytokineengineeringenablesnovelsyntheticeffectorstatesescapingcanonicalexhaustionintumorrejectingcd8tcells
AT andreattamassimo orthogonalcytokineengineeringenablesnovelsyntheticeffectorstatesescapingcanonicalexhaustionintumorrejectingcd8tcells
AT ortizmirandayaquelin orthogonalcytokineengineeringenablesnovelsyntheticeffectorstatesescapingcanonicalexhaustionintumorrejectingcd8tcells
AT mullertania orthogonalcytokineengineeringenablesnovelsyntheticeffectorstatesescapingcanonicalexhaustionintumorrejectingcd8tcells
AT rotaioannaa orthogonalcytokineengineeringenablesnovelsyntheticeffectorstatesescapingcanonicalexhaustionintumorrejectingcd8tcells
AT crespoisaac orthogonalcytokineengineeringenablesnovelsyntheticeffectorstatesescapingcanonicalexhaustionintumorrejectingcd8tcells
AT seijobili orthogonalcytokineengineeringenablesnovelsyntheticeffectorstatesescapingcanonicalexhaustionintumorrejectingcd8tcells
AT castrowilson orthogonalcytokineengineeringenablesnovelsyntheticeffectorstatesescapingcanonicalexhaustionintumorrejectingcd8tcells
AT jimenezlunacristina orthogonalcytokineengineeringenablesnovelsyntheticeffectorstatesescapingcanonicalexhaustionintumorrejectingcd8tcells
AT scarpellinoleonardo orthogonalcytokineengineeringenablesnovelsyntheticeffectorstatesescapingcanonicalexhaustionintumorrejectingcd8tcells
AT ronetcatherine orthogonalcytokineengineeringenablesnovelsyntheticeffectorstatesescapingcanonicalexhaustionintumorrejectingcd8tcells
AT spillaodrenn orthogonalcytokineengineeringenablesnovelsyntheticeffectorstatesescapingcanonicalexhaustionintumorrejectingcd8tcells
AT lanitisevripidis orthogonalcytokineengineeringenablesnovelsyntheticeffectorstatesescapingcanonicalexhaustionintumorrejectingcd8tcells
AT romeropedro orthogonalcytokineengineeringenablesnovelsyntheticeffectorstatesescapingcanonicalexhaustionintumorrejectingcd8tcells
AT luthersanjiva orthogonalcytokineengineeringenablesnovelsyntheticeffectorstatesescapingcanonicalexhaustionintumorrejectingcd8tcells
AT irvingmelita orthogonalcytokineengineeringenablesnovelsyntheticeffectorstatesescapingcanonicalexhaustionintumorrejectingcd8tcells
AT coukosgeorge orthogonalcytokineengineeringenablesnovelsyntheticeffectorstatesescapingcanonicalexhaustionintumorrejectingcd8tcells